Oncology Learning Network

Oncology Learning Network
Copanlisib Plus Rituximab Shows Superior Efficacy Over Monotherapy in FL, MZL

Copanlisib when given in combination with rituximab demonstrated superior efficacy when compared to rituximab monotherapy in patients with relapsed FL/MZL, per findings presented at ASH 2021.

Oncology Learning Network
Pralsetinib Demonstrates High Potency, Promise in Patients With RET+ NSCLC

Pralsetinib shows high potency, convenient oral administration, and selective RET inhibition in patients with RET-positive NSCLC, according to data from the ARROW study.

Oncology Learning Network
Selpercatinib Superior to Prior Systemic Therapy in RET+ NSCLC

According to data from the phase 1/2 LIBRETTO-001 trial, selpercatinib demonstrated superior clinical benefit over prior systemic therapies in patients with RET+ NSCLC.

Oncology Learning Network
Brigatinib Safe, Effective for Crizotinib-Refractory ALK+ NSCLC

According to study data being presented by Scott N.

Oncology Learning Network
Increased Risk For HZ Varies by Age, Treatment in Patients With CLL

According to study findings being presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.

Oncology Learning Network
Cirmtuzumab, Ibrutinib Therapy Well Tolerated In Both CLL/MCL

Cirmtuzumab when given in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies, according to study findings presented at the virtual 2021

Oncology Learning Network
Triplet Therapy Shows Promise in Patients With RR FL

Treatment with polatuzumab vedotin, obinutuzumab, and venecolax, shows promise in the response rates at end of induction in patients with RR FL, according to data being presented at the virtual 202

Oncology Learning Network
Experts Discourage Intensive Follow-Up of Patients Treated for Endometrial Cancer

According to findings presented at the virtual 2021 ASCO Annual Meeting, the use of frequent routine imaging and laboratory exams in patients treated for endometrial cancer should be discouraged.

Oncology Learning Network
Combo Therapy May Target MET-Dependent Resistance in RET+ NSCLC

With the help of single patient protocols, researchers discover that combining selpercatinib with crizotinib targets MET-amplified resistance found in RET+ NSCLC treated with selpercatinib alone.

Oncology Learning Network
Cemiplimab Therapy Safe, Active in Patients With Cutaneous Squamous Cell Carcinoma

Phase 2 study findings demonstrated the acceptable safety profile and antitumor activity of cemiplimab therapy for patients with locally advanced cutaneous squamous cell carcinoma.

Oncology Learning Network
Subscribe to Oncology Learning Network

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (132, 101, 173)
rgb(217, 7, 192)
rgb(2, 230, 230)